Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Abstract DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-56293-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571539817496576 |
|---|---|
| author | Katharina Bolsewig Eline A. J. Willemse Pascual Sánchez-Juan Alberto Rábano Minerva Martínez James D. Doecke Giovanni Bellomo Lisa Vermunt Daniel Alcolea Steffen Halbgebauer Sjors in ‘t Veld Niklas Mattsson-Carlgren Katerina Veverova Christopher J. Fowler Lynn Boonkamp Marleen Koel-Simmelink Zulaiga Hussainali Daimy N. Ruiters Lorenzo Gaetani Andrea Toja Juan Fortea Yolande Pijnenburg Afina W. Lemstra Wiesje M. van der Flier Jakub Hort Markus Otto Oskar Hansson Lucilla Parnetti Colin L. Masters Alberto Lleó Charlotte E. Teunissen Marta Del Campo Milán |
| author_facet | Katharina Bolsewig Eline A. J. Willemse Pascual Sánchez-Juan Alberto Rábano Minerva Martínez James D. Doecke Giovanni Bellomo Lisa Vermunt Daniel Alcolea Steffen Halbgebauer Sjors in ‘t Veld Niklas Mattsson-Carlgren Katerina Veverova Christopher J. Fowler Lynn Boonkamp Marleen Koel-Simmelink Zulaiga Hussainali Daimy N. Ruiters Lorenzo Gaetani Andrea Toja Juan Fortea Yolande Pijnenburg Afina W. Lemstra Wiesje M. van der Flier Jakub Hort Markus Otto Oskar Hansson Lucilla Parnetti Colin L. Masters Alberto Lleó Charlotte E. Teunissen Marta Del Campo Milán |
| author_sort | Katharina Bolsewig |
| collection | DOAJ |
| description | Abstract DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson’s disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring. |
| format | Article |
| id | doaj-art-b1472858793149b59718513043e28d24 |
| institution | Kabale University |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-b1472858793149b59718513043e28d242025-02-02T12:32:50ZengNature PortfolioNature Communications2041-17232025-01-011611910.1038/s41467-025-56293-zIncreased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatmentKatharina Bolsewig0Eline A. J. Willemse1Pascual Sánchez-Juan2Alberto Rábano3Minerva Martínez4James D. Doecke5Giovanni Bellomo6Lisa Vermunt7Daniel Alcolea8Steffen Halbgebauer9Sjors in ‘t Veld10Niklas Mattsson-Carlgren11Katerina Veverova12Christopher J. Fowler13Lynn Boonkamp14Marleen Koel-Simmelink15Zulaiga Hussainali16Daimy N. Ruiters17Lorenzo Gaetani18Andrea Toja19Juan Fortea20Yolande Pijnenburg21Afina W. Lemstra22Wiesje M. van der Flier23Jakub Hort24Markus Otto25Oskar Hansson26Lucilla Parnetti27Colin L. Masters28Alberto Lleó29Charlotte E. Teunissen30Marta Del Campo Milán31Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCCentro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos IIIAlzheimer’s Centre Reina Sofia-CIEN Foundation-ISCIIIAlzheimer’s Centre Reina Sofia-CIEN Foundation-ISCIIIAustralian E-Health Research Centre, CSIROSection of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of PerugiaNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCCentro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos IIIDepartment of Neurology, University Hospital UlmNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCClinical Memory Research Unit, Lund UniversityMemory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University HospitalFlorey Institute, The University of MelbourneNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCSection of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of PerugiaSection of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of PerugiaCentro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos IIIAmsterdam Neuroscience, Neurodegeneration program, Amsterdam UMCAmsterdam Neuroscience, Neurodegeneration program, Amsterdam UMCAmsterdam Neuroscience, Neurodegeneration program, Amsterdam UMCMemory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University HospitalDepartment of Neurology, University Hospital UlmClinical Memory Research Unit, Lund UniversitySection of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of PerugiaFlorey Institute, The University of MelbourneCentro de Investigación Biomédica en Red en enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos IIINeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMCAbstract DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson’s disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.https://doi.org/10.1038/s41467-025-56293-z |
| spellingShingle | Katharina Bolsewig Eline A. J. Willemse Pascual Sánchez-Juan Alberto Rábano Minerva Martínez James D. Doecke Giovanni Bellomo Lisa Vermunt Daniel Alcolea Steffen Halbgebauer Sjors in ‘t Veld Niklas Mattsson-Carlgren Katerina Veverova Christopher J. Fowler Lynn Boonkamp Marleen Koel-Simmelink Zulaiga Hussainali Daimy N. Ruiters Lorenzo Gaetani Andrea Toja Juan Fortea Yolande Pijnenburg Afina W. Lemstra Wiesje M. van der Flier Jakub Hort Markus Otto Oskar Hansson Lucilla Parnetti Colin L. Masters Alberto Lleó Charlotte E. Teunissen Marta Del Campo Milán Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment Nature Communications |
| title | Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment |
| title_full | Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment |
| title_fullStr | Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment |
| title_full_unstemmed | Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment |
| title_short | Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment |
| title_sort | increased plasma dopa decarboxylase levels in lewy body disorders are driven by dopaminergic treatment |
| url | https://doi.org/10.1038/s41467-025-56293-z |
| work_keys_str_mv | AT katharinabolsewig increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT elineajwillemse increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT pascualsanchezjuan increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT albertorabano increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT minervamartinez increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT jamesddoecke increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT giovannibellomo increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT lisavermunt increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT danielalcolea increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT steffenhalbgebauer increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT sjorsintveld increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT niklasmattssoncarlgren increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT katerinaveverova increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT christopherjfowler increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT lynnboonkamp increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT marleenkoelsimmelink increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT zulaigahussainali increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT daimynruiters increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT lorenzogaetani increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT andreatoja increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT juanfortea increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT yolandepijnenburg increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT afinawlemstra increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT wiesjemvanderflier increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT jakubhort increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT markusotto increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT oskarhansson increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT lucillaparnetti increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT colinlmasters increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT albertolleo increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT charlotteeteunissen increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment AT martadelcampomilan increasedplasmadopadecarboxylaselevelsinlewybodydisordersaredrivenbydopaminergictreatment |